Our guest is Sergey Jakimov, the Founding and Managing Partner of LongeVC, a venture capital firm dedicated to backing early-stage biotech and longevity startups. A serial entrepreneur, Sergey has co-founded ventures like Longenesis, a medical tech startup unlocking biomedical data for drug discovery, and the Longevity Science Foundation, a non-profit advancing healthy human lifespan. He’s been named to Forbes Latvia's 30 Under 30 in technology and healthcare, and via LongeVC, he invests in innovation in areas including therapeutics, d...
Our guest is Sergey Jakimov, the Founding and Managing Partner of LongeVC, a venture capital firm dedicated to backing early-stage biotech and longevity startups. A serial entrepreneur, Sergey has co-founded ventures like Longenesis, a medical tech startup unlocking biomedical data for drug discovery, and the Longevity Science Foundation, a non-profit advancing healthy human lifespan. He’s been named to Forbes Latvia's 30 Under 30 in technology and healthcare, and via LongeVC, he invests in innovation in areas including therapeutics, diagnostics, and personalized medicine.
In this episode, Sergey warns about the rising danger of misinformation disguised as health advice—where influencers and hype outpace evidence-based science. I hope you enjoy our discussion as we unpack this public health challenge and explore solutions for a more credible biotech landscape.
- 01:22 Meet Sergey Jakimov
- 06:14 Developing a longevity focus
- 10:47 A typical day at LongeVC
- 13:26 The LongeVC portfolio
- 17:28 Misinformation as health crisis
- 26:04 The harm of bad advice
- 33:16 The impact on biotech industry funding
- 36:18 Strategies for addressing misinformation
- 42:17 Optimism about trends in longevity
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
- 13 anti-aging startups on a mission to extend lives
- Turning back time with cellular reprogramming: Shift raises $16 million in seed funding
- Are European biotech VCs under pressure to scale? Time to get pragmatic
View more